{"id":"budesonide-inhalation-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":"1-5","effect":"Oral candidiasis"},{"rate":null,"effect":"Hoarseness"},{"rate":null,"effect":"Throat irritation"}]},"_chembl":null,"_dailymed":{"setId":"c52c5382-1400-44b9-95be-a30e1cf706da","title":"BUDESONIDE INHALATION SUSPENSION (BUDESONIDE) INHALANT [CIPLA USA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide acts as a selective glucocorticoid receptor agonist that decreases airway inflammation by inhibiting the release of inflammatory cytokines, chemokines, and adhesion molecules. When delivered as an inhalation suspension, it deposits directly in the lungs, providing local anti-inflammatory effects with minimal systemic absorption. This reduces airway hyperresponsiveness and mucus production in asthma and other obstructive airway diseases.","oneSentence":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:54.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy in children and adults"},{"name":"Croup (laryngotracheobronchitis)"}]},"trialDetails":[{"nctId":"NCT06067828","phase":"PHASE3","title":"A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":171},{"nctId":"NCT06283966","phase":"PHASE3","title":"A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-21","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":5000},{"nctId":"NCT06502366","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-22","conditions":"Asthma","enrollment":422},{"nctId":"NCT06368427","phase":"","title":"Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-30","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":10},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT05505734","phase":"PHASE3","title":"A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2022-09-02","conditions":"Asthma","enrollment":2516},{"nctId":"NCT06723756","phase":"PHASE1","title":"A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-23","conditions":"Healthy Participants","enrollment":105},{"nctId":"NCT06595121","phase":"PHASE1","title":"Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)","status":"COMPLETED","sponsor":"Unither Pharmaceuticals, France","startDate":"2024-08-13","conditions":"Healthy","enrollment":24},{"nctId":"NCT04933383","phase":"PHASE1, PHASE2","title":"Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics","status":"COMPLETED","sponsor":"Aquilon Pharmaceuticals S.A.","startDate":"2021-07-23","conditions":"Asthma","enrollment":23},{"nctId":"NCT04527016","phase":"PHASE4","title":"Airway Microbiota Based Treatment of Asthma in Preschool Children","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2021-10-18","conditions":"Asthma in Children","enrollment":120},{"nctId":"NCT06189586","phase":"NA","title":"Comparison of Aerosol Inhalation and Intravenous Glucocorticoid in the Treatment of Severe AECOPD","status":"UNKNOWN","sponsor":"Dong Yang","startDate":"2021-10-01","conditions":"Acute Exacerbation of Chronic Obstructive Pulmonary Disease","enrollment":100},{"nctId":"NCT05148312","phase":"PHASE1","title":"Single-dose AQ001S PK Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Aquilon Pharmaceuticals S.A.","startDate":"2021-11-12","conditions":"Pharmacokinetics","enrollment":29},{"nctId":"NCT05534685","phase":"NA","title":"Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia","status":"UNKNOWN","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2022-09-20","conditions":"Respiratory Tract Diseases","enrollment":336},{"nctId":"NCT04064684","phase":"PHASE2","title":"Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2020-02-04","conditions":"Acute Respiratory Distress Syndrome","enrollment":2},{"nctId":"NCT04848662","phase":"PHASE1","title":"To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2021-05-06","conditions":"Asthma","enrollment":12},{"nctId":"NCT05325489","phase":"PHASE3","title":"Comparison of Nebulized Budesonide and Intranasal Budesonide Spray in Children With Adenotonsillar Hypertrophy","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2022-04","conditions":"Snoring, Mouth Breathing","enrollment":100},{"nctId":"NCT04918953","phase":"PHASE2","title":"Factors Influencing the Prognosis of Olfactory Dysfunction After Upper Sensation","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-06-02","conditions":"Outcome","enrollment":90},{"nctId":"NCT03421730","phase":"PHASE1","title":"A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma","status":"COMPLETED","sponsor":"Vectura Limited","startDate":"2017-12-18","conditions":"Wheezing, Reactive Airway Disease, Mild Asthma","enrollment":17},{"nctId":"NCT03934333","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-05-16","conditions":"Relative Bioavailability","enrollment":11},{"nctId":"NCT03521063","phase":"PHASE4","title":"Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.","status":"UNKNOWN","sponsor":"Hospital Central \"Dr. Ignacio Morones Prieto\"","startDate":"2018-01-01","conditions":"Bronchopulmonary Dysplasia, Infant,Premature, Respiratory Distress Syndrome","enrollment":108},{"nctId":"NCT04032834","phase":"PHASE1","title":"A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects","status":"COMPLETED","sponsor":"Vectura Limited","startDate":"2017-02-20","conditions":"Asthma","enrollment":34},{"nctId":"NCT01687283","phase":"PHASE3","title":"Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-27","conditions":"Asthma","enrollment":316},{"nctId":"NCT03687515","phase":"PHASE3","title":"Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis.","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2015-01-01","conditions":"Chronic Rhinosinusitis With Polyposis","enrollment":91},{"nctId":"NCT01846962","phase":"PHASE4","title":"Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2012-11","conditions":"Eosinophilic Esophagitis","enrollment":64},{"nctId":"NCT02187445","phase":"PHASE1","title":"Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Sickle Cell Disease, Asthma, Acute Chest Syndrome","enrollment":36},{"nctId":"NCT02593500","phase":"PHASE1","title":"Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg","status":"COMPLETED","sponsor":"Reig Jofre Group","startDate":"2014-04","conditions":"Allergy","enrollment":57},{"nctId":"NCT01225549","phase":"PHASE2","title":"The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Asthma","enrollment":27},{"nctId":"NCT02024659","phase":"PHASE2, PHASE3","title":"Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2010-09","conditions":"Nasal Polyps","enrollment":57},{"nctId":"NCT01511302","phase":"PHASE1","title":"Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma","status":"COMPLETED","sponsor":"Revalesio Corporation","startDate":"2012-06","conditions":"Asthma","enrollment":65},{"nctId":"NCT00627679","phase":"PHASE1","title":"Safety and Blood Level Study of Unit Dose Budesonide","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-12","conditions":"Asthma","enrollment":16},{"nctId":"NCT00554970","phase":"PHASE2","title":"A Study of 2 Doses of MAP0010 in Adult Asthmatics","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-11","conditions":"Asthma","enrollment":32},{"nctId":"NCT00995904","phase":"PHASE2","title":"Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-09","conditions":"Asthma","enrollment":25},{"nctId":"NCT00961233","phase":"NA","title":"Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-10","conditions":"Eosinophilic Esophagitis","enrollment":25},{"nctId":"NCT00393367","phase":"PHASE4","title":"Budesonide Inhalation Suspension for Acute Asthma in Children","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2006-12","conditions":"Asthma, Acute Asthma, Reactive Airway Exacerbation","enrollment":179},{"nctId":"NCT01200108","phase":"PHASE2","title":"AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma","status":"COMPLETED","sponsor":"Activaero GmbH","startDate":"2010-03","conditions":"Asthma","enrollment":""},{"nctId":"NCT00855959","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Asthma","enrollment":108},{"nctId":"NCT01293734","phase":"PHASE2","title":"Research on Traditional Chinese Medicine (TCM) Clinical Treatment of the Acute Episode of Bronchial Asthma.","status":"COMPLETED","sponsor":"Liaoning University of Traditional Chinese Medicine","startDate":"2008-12","conditions":"Bronchial Asthma","enrollment":360},{"nctId":"NCT00975754","phase":"PHASE1","title":"Lung Deposition Via Different Inhalation Devices","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT00232648","phase":"PHASE3","title":"Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-01","conditions":"Asthma","enrollment":54},{"nctId":"NCT00641472","phase":"PHASE4","title":"Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-10","conditions":"Asthma","enrollment":380}],"_emaApprovals":[],"_faersSignals":[{"count":17,"reaction":"NO ADVERSE EVENT"},{"count":10,"reaction":"LIQUID PRODUCT PHYSICAL ISSUE"},{"count":10,"reaction":"POOR QUALITY PRODUCT ADMINISTERED"},{"count":7,"reaction":"OFF LABEL USE"},{"count":7,"reaction":"WRONG TECHNIQUE IN PRODUCT USAGE PROCESS"},{"count":5,"reaction":"PRODUCT QUALITY ISSUE"},{"count":5,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":4,"reaction":"COUGH"},{"count":4,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"PRODUCT PACKAGING QUANTITY ISSUE"}],"_approvalHistory":[{"date":"20210406","type":"SUPPL","sponsor":"CIPLA","applicationNumber":"ANDA205710"},{"date":"20171116","type":"ORIG","sponsor":"CIPLA","applicationNumber":"ANDA205710"},{"date":"20211116","type":"SUPPL","sponsor":"CIPLA","applicationNumber":"ANDA205710"}],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pulmicort Respules","Pulmicort Respules®","inhaled corticosteroids"],"phase":"marketed","status":"active","brandName":"Budesonide inhalation suspension","genericName":"Budesonide inhalation suspension","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Asthma maintenance therapy in children and adults, Croup (laryngotracheobronchitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}